Apollo Hospitals Shares Jump to Record on Healthtech Arm Spinoff
The stock jumped as much as 4.7% after it said late Monday it will merge pharmacy business Apollo Healthco Ltd. and wholesale distributor Keimed Pvt. with Apollo Healthtech and list the newly created unit in 18 to 21 months.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
41 minutes ago
- CNN
Four babies in Gaza crammed into one ICU cot struggle to stay alive
CNN's Paula Hancocks reports on the situation in Gaza, where doctors try to keep preterm babies alive in a warzone where formula, medicine and fuel are in short supply.
Yahoo
an hour ago
- Yahoo
Encompass Health announces date of 2025 second quarter earnings call
BIRMINGHAM, Ala., July 9, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2025, after the market closes on Monday, Aug. 4, 2025. The Company will host an investor conference call at 10 a.m. ET on Tuesday, Aug. 5, 2025, to discuss its results. The conference call may be accessed by dialing 800-343-4849 and providing the conference ID EHCQ225. International callers should dial 203-518-9848 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected. A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 168 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America. For more information, visit or follow us on our newsroom, X, Instagram and Facebook. From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license. Media contact:Polly Manuel | 205-970-5912media@ Investor Relations contact:Mark Miller | View original content to download multimedia: SOURCE Encompass Health Corp. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Centene Stock Down 40% — May Slide On $1 Trillion Medicaid Cuts
The Big Beautiful Bill Act cuts $1 trillion from Medicaid from which Centene gets 58% of its revenue. After plunging 40% will the stock drop more? INDIA - 2025/07/03: In this photo illustration, the Centene Corporation logo is seen displayed on a ... More smartphone and in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Key Facts On July 1, Centene withdrew its 2025 guidance following an independent actuary's estimate that the company's Obamacare revenue assumptions were too high. Centene's stock plunged 40% on July 2 and has stayed down. On July 4, the BBBA became law — and is forecast to slash $1 trillion from Medicaid which accounted for 62% of Centene's 2024 revenue. S&P Global Ratings is considering downgrading Centene's credit rating to junk status. Saint Louis, Missouri-based Centene — a provider of health care to Medicaid, Medicare, and Health Insurance Marketplace patients — suffered a 40% drop in its stock price on July 2, according to Google Finance . The drop in Centene's stock price followed the company's withdrawal of its 2025 revenue guidance. The reason? An actuarial report suggested lower than expected growth in Affordable Care Act marketplaces. In light of this report, Centene estimated 'the 2025 risk adjustment transfer to be about $1.8 billion lower than its expectations,' reported Fierce Healthcare . Since then, Centene has been faced with more bad news. The July 4 passage of the BBBA could cut $1 trillion from Medicaid in the next decade — which accounted for 62% of Centene's 2024 revenue, according to the company's 2024 Form 10-K. This could further diminish the company's growth potential. What's more, S&P Global Ratings is evaluating whether to downgrade Centene's credit rating to junk, according to Becker's — which could raise the company's cost of capital. These developments raise questions for investors, such as: Will S&P Global cut Centene's credit rating to junk status? If so, how much will Centene's cost of capital rise? How will Centene's net cash flow be affected by this? If the BBBA cuts $1 trillion from Medicaid, how much will Centene's revenue and net income drop? Can Centene offset that drop with other business lines? If so, how? I have contacted Centene to request comment and will update this post if I receive a response. Centene makes money by providing healthcare services to patients who are receive finding through government programs such as Medicaid, Medicare, and the Affordable Care Act Marketplaces. Medicaid — which contributed $101.4 billion to Centene's 2024 revenue — accounted for 62% of the company's total revenue. Medicare contributed 14% to Centene's 2024 top line and Commercial — the Marketplace business unit — accounted for 21% of the total and grew 36% to $33.7 billion, according to Centene's 2024 Form 10-K. Rapid growth in Centene's Marketplace business helped the company exceed expectations and raise guidance in the first quarter of 2025. Here are the highlights: First quarter 2025 revenue: $46.6 billion — up 15.4% and 7.2% higher than the consensus, according to Zacks Equity Research . — up 15.4% and 7.2% higher than the consensus, according to . Q1 2025 adjusted earnings per share: $2.90 — 22.9% more than the Zacks Consensus Estimate. — 22.9% more than the Zacks Consensus Estimate. 2025 revenue forecast: a range between $178.5 billion and $181.5 billion — the midpoint of which implies 10.4% growth, Zacks reported. — the midpoint of which implies 10.4% growth, Zacks reported. 2025 adjusted EPS forecast: greater than $7.25 — 1.1% more than in 2024, noted Zacks. Centene's strong product and market growth in the Marketplace business helped propel a 31% growth in the company's commercial revenues to $10.1 billion in the first quarter of 2025. Centene's premiums advanced 17.4% to $41.7 billion — exceeding analyst estimates, noted Zacks . Why Centene Slashed Its 2025 Revenue Guidance The strong growth in Centene's Marketplace business in the first quarter likely shocked investors when the health insurer withdrew its 2025 forecast over concerns with Obamacare, reported Reuters . Specifically, the company reported slower market growth and a rise in higher-risk patients enrolled in its plans under Obamacare. The insurer said an analysis from Wakely predicted 'market growth in 22 of its states will fall short of expectations,' Fierce Healthcare reported — reducing Centene's 2025 EPS forecast by $2.75. The negative impact on the insurer's adjusted EPS could be even worse. It is not "out of the realm of possibility" that Centene's earlier 2025 profit forecast of at least $7.25 per share is cut in half, Mizuho analyst Ann Hynes told Reuters . How Much The Bbba Will Reduce Medicaid Spending A bigger threat to Centene's growth could be the $1 trillion reduction in Medicaid spending over the next decade, according to my July Forbes post. These cuts are likely to cause widespread pain, such as: Loss of coverage. 15.9 million Americans could lose Medicaid coverage, according to the Urban Institute. 15.9 million Americans could lose Medicaid coverage, according to the Urban Institute. Rising expenses and cost cuts. Hospitals' expenses for Medicaid patients could fall by $37 billion, estimated the Commonwealth Fund ; to offset the lower revenue, hospitals, nursing homes, and doctors' offices could eliminate 477,000 jobs, according to the American Association of Medical Colleges , and Hospitals' expenses for Medicaid patients could fall by $37 billion, estimated the ; to offset the lower revenue, hospitals, nursing homes, and doctors' offices could eliminate 477,000 jobs, according to the , and Hospital closures and patient disruption. many rural hospitals may be forced to close, forcing patients to travel further for care, noted the American Hospital Association . Moreover the drop in Medicaid could trim Centene's revenue growth. Specifically, Medicaid and individual exchange headwinds could reduce the company's growth rate by one percentage point from 5% to 4% annually over the next five years, according to Morningstar analyst Julie Utterback. Will S&p Global Ratings Give Centene A Junk Rating? Moody's has already rated Centene as Ba1, its highest junk grade, according to Bloomberg . S&P Global Ratings is considering downgrading Centene's credit to junk status reported Becker's . S&P cited the loss of visibility into Centene's future profitability. 'With the removal of earnings guidance, we have less immediate clarity and confidence on the company's capital adequacy trajectory, as well as the overall strength of its business and execution capabilities,' S&P said in a July 1 release. A potential downgrade could remove Centene from major high-grade bond indexes, boosting borrowing costs. While Centene paid an average interest rate of about 3.8% in March 2025, a downgrade could increase that rate significantly. noted Bloomberg . Is Centene Stock A Bargain Or Will It Fall Further? Centene stock could fall further. In the wake of the company withdrawing guidance, Jim Cramer sounded very pessimistic. 'Given this news from Centene, I think the whole managed care industry is borderline un-investable right now,' Cramer said on CNBC. He described Centene's expected 2025 hit to EPS as 'horrifying.' Cramer added 'And, unfortunately, things will get worse for this sector before they get better, so I just can't justify telling you to own these stocks right now, even after they've already come down so dramatically.' On a more upbeat note, 15 Wall Street analysts view Centene as significantly under-valued. With an average 12 month price target of $63.08, analysts see nearly 91% upside in the shares, noted TipRanks .
